Streetbeat News

SPRY

ARS Pharmaceuticals, Inc.

Industry

Biotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Open

14.19

Mkt cap

1.4B

Volume

1.5M

High

14.32

P/E Ratio

-29.81

52-wk high

18.51

Low

13.36

Div yield

N/A

52-wk low

4.53

ARS Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) for neffy 1 mg, aimed at treating Type I allergic reactions, including anaphylaxis, in children weighing 15 to 30 kg.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 8:49 pm

Analysts have provided mixed ratings for ARS Pharmaceuticals (NASDAQ:SPRY) over the past three months, with a recent average price target of $25.0. The company has shown significant revenue growth and maintains a strong financial position despite challenges in asset utilization.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 4:15 pm

ARS Pharmaceuticals has launched pre-ordering services for neffy, an epinephrine nasal spray approved by the FDA for treating Type I Allergic Reactions, including anaphylaxis. The product is expected to be available by late September.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 12:19 pm

ARS Pharmaceuticals' EURneffy adrenaline nasal spray has been approved by the European Commission for emergency treatment of severe allergic reactions, marking the first new delivery method in the EU in over 30 years.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 1:30 pm

ARS Pharmaceuticals' Neffy, a needle-free nasal spray for allergic reactions, has been FDA approved. It offers convenience over traditional EpiPens but faces skepticism regarding real-world efficacy. Neffy is easier to carry and has a longer shelf life, but concerns about insurance coverage and effectiveness during actual emergencies remain.

Portfolio Pulse from Vandana Singh

August 23, 2024 | 3:43 pm

ARS Pharmaceuticals shares declined after Cantor Fitzgerald initiated coverage with an Overweight rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 3:40 pm

ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, has been approved by the FDA for emergency allergic reactions. Cantor Fitzgerald initiated coverage with an Overweight rating and a $30 price target, citing Neffy's potential to capture 30% market share and change the allergy treatment paradigm.

Portfolio Pulse from Vandana Singh

August 20, 2024 | 4:21 pm

Fabrinet and several other companies saw significant stock price increases on Tuesday due to strong earnings reports and positive news. Fabrinet's shares rose 18.2% after reporting better-than-expected earnings and issuing strong guidance. Other notable gainers included Bit Digital, NANO Nuclear Energy, Tempus AI, Amer Sports, Hawaiian Holdings, and Palo Alto Networks.

Portfolio Pulse from Avi Kapoor

August 20, 2024 | 2:07 pm

Cantor Fitzgerald has initiated coverage on ARS Pharmaceuticals with an Overweight rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 9:43 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.